leadf
logo-loader
viewTyraTech, Inc.

Fresh start for Tyratech with new strategic focus on animal health

Bruno Jactel, chief executive of Tyratech Inc. (LON:TYR LON:TYRU) chats to Proactive's Andrew Scott about the proposed sale of Vamousse to Alliance Pharma plc (AIM: APH).

It's for an initial cash consideration of $13mln with Tyratech potentially being entitled to further performance-based payments of up to $4.5 million.

Jactel also outlines their new strategic focus on animal health and the plans they've got to maximise opportunities in what's a $6bln market.

Quick facts: TyraTech, Inc.

Price: - -

AIM:TYR
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Chesnara raises dividend and reports profit of £66.6m in 'extraordinary half...

Chesnara PLC's (LON:CSN) John Deane joins Proactive to discuss their latest results, which show a £66.6m profit. Deane refers to the 'extraordinary half year' and believes there will be an impact on new business as a consequence in the latter part of the year. He goes to explain the...

2 hours, 39 minutes ago

2 min read